Compare EVI & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVI | ADCT |
|---|---|---|
| Founded | 1959 | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 204.6M | 192.7M |
| IPO Year | 1995 | 2019 |
| Metric | EVI | ADCT |
|---|---|---|
| Price | $20.01 | $1.29 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $3.33 |
| AVG Volume (30 Days) | 92.8K | ★ 1.2M |
| Earning Date | 11-09-2026 | 11-09-2026 |
| Dividend Yield | ★ 1.58% | N/A |
| EPS Growth | N/A | ★ 30.86 |
| EPS | ★ 0.24 | N/A |
| Revenue | ★ $389,830,000.00 | $81,357,000.00 |
| Revenue This Year | $8.40 | N/A |
| Revenue Next Year | $4.71 | $25.89 |
| P/E Ratio | $87.00 | ★ N/A |
| Revenue Growth | 10.26 | ★ 14.85 |
| 52 Week Low | $12.75 | $0.78 |
| 52 Week High | $27.00 | $4.98 |
| Indicator | EVI | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 44.93 | 42.68 |
| Support Level | $19.93 | $0.97 |
| Resistance Level | $21.37 | $1.45 |
| Average True Range (ATR) | 1.50 | 0.17 |
| MACD | -0.28 | -0.04 |
| Stochastic Oscillator | 6.35 | 9.60 |
EVI Industries Inc is a value-added distributor and service provider in the commercial laundry industry. It sells and leases commercial laundry equipment, specializing in washing, drying, finishing, material handling, water heating, power generation, and water reuse applications. The company supports its equipment offerings with installation, maintenance, and repair services through a large network of trained technicians. It serves a wide range of customers, including commercial, industrial, institutional, government, and retail sectors. Geographically, the company serves various countries including United States, Canada, the Caribbean, and Latin America.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).